The partnership makes the bimodal neuromodulation device for tinnitus available through clinics in Philadelphia and Charlotte.
Neuromod Devices Ltd has partnered with Treble Health to expand the availability of the Lenire tinnitus treatment device for patients in Philadelphia and Charlotte.
The collaboration provides patient access to Lenire through two Treble Health network practices: Audiology & Hearing Services of Charlotte and The Tinnitus Treatment Center of Philadelphia. Treble Health is a hearing health service specializing in tinnitus treatment that operates a hybrid care model of telehealth and in-person clinics.
“Expanding the awareness and availability of Lenire to tinnitus patients in the USA and globally is a priority for Neuromod,” says Eric Timm, president, global commercial operations & CEO, Neuromod USA Inc, in a release. “I’m delighted this partnership with Treble Health will give people living with tinnitus broader access to treatment with Lenire supported by guidance from expert clinicians.”
Device Technology and Clinical Data
Lenire is a bimodal neuromodulation device that combines audio tones delivered through headphones with mild electrical pulses delivered to the tongue’s surface via a proprietary Tonguetip device. Under the care of an audiologist, patients with bothersome tinnitus typically use the device at home for two 30-minute sessions daily for approximately 12 weeks.
A recent study of 140 US patients published in the American Journal of Audiology found that 81.8% of patients with moderate or worse tinnitus demonstrated a clinically significant improvement after about 12 weeks of treatment with Lenire.
“The Lenire device has been an outstanding addition to our tinnitus treatment options as clinicians,” says Gail Brenner, AuD, tinnitus specialist at The Tinnitus Treatment Center of Philadelphia, in a release. “It gives us another intervention that has proven to benefit the vast majority of tinnitus patients. I am delighted to make it available to my patients as part of Treble Health.”
“I’m delighted to make Lenire available to tinnitus patients at these two Treble Health in-person clinics,” says Ben Thompson, AuD, founder of Treble Health, in a release. “Since Lenire’s De Novo approval by the US FDA in 2023 we have seen evidence of great treatment outcomes for patients be peer-reviewed and published in respected scientific journals. These results make it clear that Lenire is an extremely strong treatment option for tinnitus patients.”
Featured image: Gail Brenner, AuD, holding the Lenire device at Treble Health Tinnitus Treatment Center of Philadelphia. Photo: Treble Health and Neuromod
